DUBLIN–(BUSINESS WIRE)–The “Global
Genetic disorders Partnering 2014-2019: Deal Trends, Players and
Financials” report has been added to ResearchAndMarkets.com’s
offering.
Global Genetic Disorders Partnering 2014 to 2019 provides the full
collection of Genetic Disorders disease deals signed between the world’s
pharmaceutical and biotechnology companies since 2014.
Most of the deals included within the report occur when a licensee
obtains a right or an option right to license a licensor’s product or
technology. More often these days these deals tend to be multi-component
including both a collaborative R&D and a commercialization of outcomes
element.
The report takes readers through the comprehensive Genetic Disorders
disease deal trends, key players and top deal values allowing the
understanding of how, why and under what terms companies are currently
entering Genetic Disorders deals.
The report presents financial deal terms values for Genetic Disorders
deals, where available listing by overall headline values, upfront
payments, milestones and royalties enabling readers to analyse and
benchmark the value of current deals.
The initial chapters of this report provide an orientation of Genetic
Disorders dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Genetic Disorders
dealmaking since 2014 covering trends by year, deal type, stage of
development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline
value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Genetic Disorders deals since
2014. Deals are listed by headline value. The chapter includes the top
25 most active Genetic Disorders dealmakers, together with a full
listing of deals to which they are a party. Where the deal has an
agreement contract published at the SEC a link provides online access to
the contract.
Chapter 5 provides comprehensive access to Genetic Disorders deals since
2014 where a deal contract is available, providing the user with direct
access to contracts as filed with the SEC regulatory authorities. Each
deal title links via Weblink to an online version of the deal record
contract document, providing easy access to each contract document on
demand.
Chapter 6 provides a comprehensive directory of all Genetic Disorders
partnering deals by specific Genetic Disorders target announced since
2014. The chapter is organized by specific Genetic Disorders therapeutic
target. Each deal title links via Weblink to an online version of the
deal record and where available, the contract document, providing easy
access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of
all Genetic Disorders partnering deals signed and announced since 2014.
The appendices are organized by company A-Z, stage of development at
signing, deal type (collaborative R&D, co-promotion, licensing etc) and
technology type. Each deal title links via Weblink to an online version
of the deal record and where available, the contract document, providing
easy access to each contract document on demand.
Report Scope
Global Genetic Disorders Partnering 2014 to 2019 includes:
-
Trends in Genetic Disorders dealmaking in the biopharma industry since
2014 - Analysis of Genetic Disorders deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Genetic Disorders deal contract documents
- Comprehensive access to over 3500 Genetic Disorders deal records
- The leading Genetic Disorders deals by value since 2014
- Most active Genetic Disorders dealmakers since 2014
Available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Genetic Disorders dealmaking
2.1. Introduction
2.2. Genetic Disorders partnering over the years
2.3. Genetic Disorders partnering by deal type
2.4. Genetic Disorders partnering by industry sector
2.5. Genetic Disorders partnering by stage of development
2.6. Genetic Disorders partnering by technology type
2.7. Genetic Disorders partnering by therapeutic indication
Chapter 3 -Financial deal terms for Genetic Disorders partnering
3.1. Introduction
3.2. Disclosed financials terms for Genetic Disorders partnering
3.3. Genetic Disorders partnering headline values
3.4. Genetic Disorders deal upfront payments
3.5. Genetic Disorders deal milestone payments
3.6. Genetic Disorders royalty rates
Chapter 4 – Leading Genetic Disorders deals and dealmakers
4.1. Introduction
4.2. Most active in Genetic Disorders partnering
4.3. List of most active dealmakers in Genetic Disorders
4.4. Top Genetic Disorders deals by value
Chapter 5 – Genetic Disorders contract document directory
5.1. Introduction
5.2. Genetic Disorders partnering deals where contract document available
Chapter 6 – Genetic Disorders dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Genetic Disorders therapeutic target
Appendices
Appendix 1 – Directory of Genetic Disorders deals by company A-Z 2014 to
2019
Appendix 2 – Directory of Genetic Disorders deals by deal type 2014 to
2019
Appendix 3 – Directory of Genetic Disorders deals by stage of
development 2014 to 2019
Appendix 4 – Directory of Genetic Disorders deals by technology type
2014 to 2019
For more information about this report visit https://www.researchandmarkets.com/research/zbdtnn/global_genetic?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Pharmaceuticals